This is a retinoic acid responsive CFP reporter allele. In this allele, the Rosa26 promoter was modified using RMCE, replacing DNA sequences from -60 to +81 with a multimerized retinoic acid response element (DR5) fused to a TATA box. 

Record History
Added on July 19, 2010 at 10:17 AM by Magnuson, Mark
Modified on October 31, 2019 at 2:25 PM by Skelton, Jennifer
Shared with (contributions)
VCMR: Vanderbilt Cryopreserved Mouse Repository
Request this Mouse Line

Mouse Information

Common Name Rosa26R26-60-DR5-TA-Cerulean
Date Cryopreserved 2010-03-16
Method of Cryopreservation Sperm
Trial IVF % Fertilization 6.00%

Genetic Alteration

Mutation #1: RMCE Targeted Mutagenesis
Allele Name: targeted mutation 1.1
Symbol: Gt(ROSA)26Sortm1.1(R26-60-DR5-Cerulean)Mgn
Zygosity at cryopreservation Heterozygote
PCR Genotyping Protocol R2660_and_228_genotyping_protocol.docx
Partial promoter substitutions generating transcriptional sentinels of diverse signaling pathways in embryonic stem cells and mice. (2012) Dis Model Mech 5: 956-66 (Added 11/6/2013)
PMID: 22888097

Background Strain Information

Strain Type Congenic Strain
Chimera/Founder Genetic Background 129S6/SvEvTac
Cryopreservation Strain Background (VCMR) C57BL/6J
Viability and Fertility Data

Strain Background:  96.97% C57Bl6/J at cryopreservation.

Heterozygous viable and fertile.

Additional Information

Through homologous recombination in ES cells, a 5.165 kb region of the Rosa26 gene containing exon 1 was replaced by a floxed tk-neo cassette, a puromycin-delta-TK fusion gene driven by the mouse phosphoglycerol kinase promoter (puroR-delta-TK) and a neomycin resistant gene driven by the bacterial EM7 promoter (EM7neo) flanked by minimal (34 bp) tandemly oriented lox71 and lox2272 sites (Cre-recombinase recognition sequences).


Document r2660dr5tacerh_pcr_protocol.doc - Added on July 27, 2010 at 1:55 PM by Jill Lindner

PCR protocol for genotyping mice

Document R26-60-DR5-TA-Cerulean.png - Added on July 19, 2010 at 10:17 AM by Mark Magnuson

Rosa26-60-DR5-TA-Cerulean gene targeting and RMCE strategy.